FOLH1 and prostate cancer: For comparison, ratio of activity uptake in kidneys and in tumors for [125I]I-BO530 was better than reported for 177Lu-PSMA-617 that nowadays is actively used for treatment of prostate cancer patients: initial uptake of 177Lu-PSMA-617 in kidneys was at least 10-fold higher than in tumors [30].The activity uptake in the intestines, muscle, and bone was low and almost diminished at 24 h pi.